1 / 22

Absorptive Kinetics of Transdermal Fentanyl

Absorptive Kinetics of Transdermal Fentanyl. Robert Leonard, PharmD candidate University of Florida College of Pharmacy. Overview. Rationale Barriers TTS-fentanyl Pharmacokinetics Studies of pharmacokinetic variability. Rationale. Continuous infusion Noninvasive nature

chaela
Download Presentation

Absorptive Kinetics of Transdermal Fentanyl

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Absorptive Kinetics of Transdermal Fentanyl Robert Leonard, PharmD candidate University of Florida College of Pharmacy

  2. Overview • Rationale • Barriers • TTS-fentanyl • Pharmacokinetics • Studies of pharmacokinetic variability

  3. Rationale • Continuous infusion • Noninvasive nature • Special populations • Protracted vomiting • Dysphagia • Less frequent dosing

  4. Barriers • Epidermal microflora • Stratum corneum • Subcutaneous vasculature • Physicochemical properties • MW • Lipophilicity

  5. TTS-fentanyl

  6. Pharmacokinetics

  7. Kinetics • Absorption • F = 0.92 • Protein binding = 79 - 97% • Tmax = 35 hours • Distribution • Vd = 3 – 8 L/kg • Metabolism • CYP3A4 • Major: norfentanyl • Minor: hydroxyfentanyl, hydroxynorfentanyl, despropionylfentanyl

  8. Kinetics

  9. Kinetics • Elimination • Cl = 34.2 – 52.8L/hr • T1/2 = 17hrs (after removal)

  10. Study • Solassol I, Caumette L, Bressolle F, et al. “Inter- and intra-individual variation in transdermal fentanyl absorption in cancer pain patients.” Oncology Reports 14:1029-1036, 2005.

  11. Absorption Kinetics

  12. Absorption Kinetics

  13. Absorption Kinetics 125 mcg/hr 175 mcg/hr 100 mcg/hr

  14. Results • Significant findings (P < 0.05) • Age: <65, 65-75, >75 • P = 0.030 • Primary cancer location: head and neck, GI, GU, Lung, Brest, others • P = 0.006 • Findings approaching significance (P ≤ 0.06) • Occlusive bandage: yes, no • P = 0.060 • Temperature: <38, 38-40, >40 • P = 0.051

  15. Limitations • Indirect assay

  16. Study • Ashburn MA, Ogden LL, Zhang J, et al. “The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat.” The Journal of Pain 4: 291-297, 2003.

  17. Absorption Kinetics

  18. Absorption Kinetics

  19. Clinical Pearls • Avoid cutting patches. • Avoid occlusive bandages. • Avoid heat. • Dose according to patient response. • Sustained release after removal.

  20. References Ashburn MA, Ogden LL, Zhang J, et al. “The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat.” The Journal of Pain 4: 291-297, 2003. Grond S, Radbruch L, Lehmann K. “Clinical pharmacokinetics of transdermal opioids: Focus on transdermal fentanyl.” Clinical Pharmacokinetics 38: 59-89, 2000. Muijsers RB, Wagstaff AJ. “Transdermal fentanyl: An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.” Drugs 61:2289-2307, 2001. Solassol I, Caumette L, Bressolle F, et al. “Inter- and intra-individual variation in transdermal fentanyl absorption in cancer pain patients.” Oncology Reports 14:1029-1036, 2005.

More Related